Peptides that mimic ‘good cholesterol’ reverse inflammatory bowel disease in mice
FINDINGSPeptides that mimic the function of HDL cholesterol, which has been dubbed “good cholesterol,” can treat the underlying inflammation associated with inflammatory bowel disease, or IBD, according to new research in mice. The same work revealed new details on how IBD can develop and what other types of drugs may wo rk to treat the disease.BACKGROUNDThe most common types of IBD, a chronic inflammatory disease of the digestive tract, are Crohn ’s disease and ulcerative colitis. There are few effective treatments for IBD, and a majority of patients will eventually need surgery, according to previous studies. Researchers already knew that people with IBD have lower levels of ApoA-I, the main protein component of HDL, in their colons compa red to healthy people. ApoA-I also is known to ease inflammation and act as an antioxidant — which can prevent cell damage — elsewhere in the body.METHODUCLA researchers studied mice that had been genetically engineered to develop molecular changes, inflammation and symptoms similar to that seen in people with Crohn ’s disease. The team detailed how IBD developed in these mice, pinpointing some new key pathways and molecules in the process. They then treated the mice with two oral drugs, one designed to mimic ApoA-I and another designed to mimic a specific inflammation-resolving molecule. Each of the compound s successfully eased inflammation in the intestines of the mice and lowered the leve...
Our weekly series of diabetes humor at DiabetesMine features a features a cartoon by Jon Carter.
CONCLUSIONS: Patients with PSC show significantly higher than average risk for the development of hepatobiliary and colonic malignancies including cholangiocarcinoma, gallbladder carcinoma and colorectal carcinoma. Yearly ultrasound surveillance followed with more definitive cross sectional imaging is prudent to arrive in a timely diagnosis of carcinoma, reducing morbidity and mortality. PMID: 31220911 [PubMed - as supplied by publisher]
TYPE 2 diabetes occurs when poor insulin production fails to control blood glucose levels. In certain cases, a person ’s blood sugar level can dip below normal levels. This sign may indicate you are at risk.
I volunteer at a free medical clinic for low income and uninsured individuals. My position is in the back office, where we call patients in from the waiting room to interview them and record basic vitals in their chart before they see the doctor. I ask the patient's birthdate to confirm, then take height, weight, blood pressure (automatic), temperature, and record respiratory rate. On rarer occasions I do finger pricks to test blood sugar for diabetic patients, or ask female OBGYN patients a... Are volunteers ethically allowed to do this?
Conclusions: Majority of the children with DPDS do not develop a symptomatic recurrence of PFC after the removal of cystogastric stents. DPDS may be a risk factor for the development of new-onset diabetes. However, future prospective studies are needed.
Conclusions: In conclusion, appropriately targeted IC in the management of children with GI symptoms is a safe, fast, and useful investigation. TI intubation rates of 100% are achievable and desirable and can be conducted quickly. Poor bowel preparation impacts negatively on this and IC duration may be faster in younger children. High diagnostic yields have been recorded in patients with a clinical suspicion of IBD. Diagnostic yield in isolated recurrent abdominal pain is low. Training to excellence in pediatric IC should be a persistent goal.
Conclusions: Our results suggest that ustekinumab is efficacious and safe in pediatric patients with IBD. Controlled clinical trial data are needed to confirm these observations.
Objectives: Subtherapeutic drug concentrations contribute to both primary and secondary nonresponse to infliximab in children with Crohn disease (CD). The aim of this study was to evaluate treatment outcomes and infliximab concentrations at infusions 2 and 3 with an objective to establish infliximab targets during induction for primary responders. Methods: Single-center, prospective cohort of anti- tumor necrosis factor-alpha naïve CD patients younger than 22 years starting infliximab. Clinical response was defined with the weighted pediatric CD activity index at the fourth infusion. Rates of biological response ...
Conclusions: Standard FC-ELISA for FC evaluation is more reliable predictor of mucosal healing than the FC-IBDoc in paediatric patients with inflammatory bowel disease. The cut-off values for both tests were incongruous.
Conclusions: ASCA-positive children with CD present with more extensive (endoscopic) and clinically severe disease. ASCA IgG is a useful prognostic marker among children with CD who receive biologics.
More News: Allergy | Allergy & Immunology | Antidoxidants | Cardiology | Centers for Disease Control and Prevention (CDC) | Cholesterol | Crohn's Disease | Diabetes | Drugs & Pharmacology | Endocrinology | Funding | Genetics | Grants | Heart | Infectious Diseases | Inflammatory Bowel Disease | National Institutes of Health (NIH) | OBGYN | Pharmaceuticals | Study | Ulcerative Colitis | Universities & Medical Training | Urology & Nephrology | Websites